A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to identify the doses of the azacitidine (AZA) tablets and
cedazuridine (CED) tablets which achieve a total AUC for AZA comparable to that for AZA
injection at 75 mg/m2